Sei Investments Co. grew its holdings in shares of Amgen Inc. (NASDAQ:AMGN – Free Report) by 1.5% in the 1st quarter, Holdings Channel reports. The fund owned 356,625 shares of the medical research company’s stock after acquiring an additional 5,320 shares during the period. Sei Investments Co.’s holdings in Amgen were worth $125,474,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also modified their holdings of the company. Norges Bank acquired a new stake in Amgen during the 4th quarter valued at approximately $2,164,162,000. Capital World Investors raised its position in shares of Amgen by 22.9% in the 4th quarter. Capital World Investors now owns 23,097,711 shares of the medical research company’s stock valued at $7,560,249,000 after purchasing an additional 4,302,237 shares in the last quarter. State Street Corp raised its position in shares of Amgen by 4.4% in the 4th quarter. State Street Corp now owns 30,591,403 shares of the medical research company’s stock valued at $10,012,872,000 after purchasing an additional 1,287,310 shares in the last quarter. Geode Capital Management LLC boosted its stake in shares of Amgen by 7.8% during the 4th quarter. Geode Capital Management LLC now owns 14,303,294 shares of the medical research company’s stock valued at $4,665,822,000 after buying an additional 1,035,779 shares during the last quarter. Finally, Amundi boosted its stake in shares of Amgen by 41.1% during the 4th quarter. Amundi now owns 3,396,945 shares of the medical research company’s stock valued at $1,111,854,000 after buying an additional 988,856 shares during the last quarter. 76.50% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analyst Weigh In
A number of research firms have recently weighed in on AMGN. Daiwa Securities Group decreased their price target on shares of Amgen from $410.00 to $390.00 and set an “outperform” rating for the company in a research report on Wednesday, May 13th. Weiss Ratings cut shares of Amgen from a “buy (b)” rating to a “buy (b-)” rating in a report on Wednesday, July 15th. Cantor Fitzgerald reiterated a “neutral” rating and set a $350.00 price objective on shares of Amgen in a research note on Monday, July 6th. Piper Sandler reissued an “overweight” rating on shares of Amgen in a report on Friday, June 12th. Finally, The Goldman Sachs Group set a $389.00 target price on shares of Amgen in a research report on Friday, June 5th. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, fifteen have issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $356.62.
Insider Transactions at Amgen
In other Amgen news, SVP Nancy A. Grygiel sold 1,237 shares of Amgen stock in a transaction that occurred on Monday, May 4th. The stock was sold at an average price of $323.73, for a total value of $400,454.01. Following the completion of the transaction, the senior vice president directly owned 7,009 shares in the company, valued at $2,269,023.57. The trade was a 15.00% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. 0.85% of the stock is owned by corporate insiders.
Amgen Stock Up 1.5%
Shares of NASDAQ:AMGN opened at $371.50 on Friday. The company’s fifty day moving average is $350.28 and its two-hundred day moving average is $351.63. The company has a debt-to-equity ratio of 5.65, a quick ratio of 1.01 and a current ratio of 1.26. Amgen Inc. has a 1-year low of $269.77 and a 1-year high of $391.29. The stock has a market capitalization of $200.50 billion, a price-to-earnings ratio of 25.85, a price-to-earnings-growth ratio of 3.70 and a beta of 0.41.
Amgen (NASDAQ:AMGN – Get Free Report) last posted its quarterly earnings results on Thursday, April 30th. The medical research company reported $5.15 EPS for the quarter, beating the consensus estimate of $4.77 by $0.38. Amgen had a net margin of 20.96% and a return on equity of 137.41%. The business had revenue of $8.62 billion during the quarter, compared to analyst estimates of $8.58 billion. During the same period in the previous year, the business posted $4.90 EPS. The company’s quarterly revenue was up 5.8% on a year-over-year basis. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. Equities analysts anticipate that Amgen Inc. will post 22.31 EPS for the current year.
About Amgen
Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.
Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.
Featured Stories
- Five stocks we like better than Amgen
- Premium Retail’s Stress Test Is Separating Winners From Losers
- D-Wave Quantum or a Quantum ETF: Which Is the Better Bet?
- GE Vernova Just Sent a Mixed AI Signal to Investors
- Alphabet Crushed Earnings, But One Number Spooked the Market
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN – Free Report).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.
